Navigation Links
KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Date:8/26/2013

NORTH LIBERTY, Iowa, Aug. 26, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201 (benzhydrocodone and acetaminophen), which the company anticipates filing in the second quarter of 2014.

In a two-stage, single and multiple-dose, oral pharmacokinetic (PK) study in 26 healthy volunteers, KP201 effectively released and achieved steady-state plasma concentrations of hydrocodone, its active metabolite hydromorphone and acetaminophen.  The data also confirmed that KP201 was metabolized completely and that no systemic prodrug exposure was observed in any subject at any time point during the study.  KP201 was also shown to be safe and well tolerated by the opioid-naive volunteers in the study.

Sven Guenther, Ph.D., Vice President of Research at KemPharm, commented, "The results of this study confirm two key benefits of KP201 and of our novel prodrug approach to abuse deterrence: 1) single and multiple doses of KP201 tablets release hydrocodone effectively only upon oral administration, and 2) the prodrug itself is metabolized completely and does not reach the systemic circulation, even at the maximum daily dose.  In the coming months, we anticipate reporting additional bioavailability and bioequivalence data that we expect will affirm the unique physicochemical and pharmacological attributes of KP201."

Travis C. Mickle, Ph.D., President and CEO of KemPharm, added, "This data set is an important milestone for KemPharm as it marks one of several clinical and non-clinical studies of KP201 that we expect to complete in preparation for the filing of an NDA in the second q
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
3. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
4. Sectra Demonstrates Radiation Dose Monitoring System at AHRA and AAPM Meetings
5. New Data From Partners Center For Connected Health Demonstrates Wireless Mobile Technology Improves Patient Engagement, Outcomes
6. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
9. New Cardiac Electrical Biomarker Featured In Johns Hopkins Abstract Demonstrates Strong Correlation To High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury
10. MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
11. West Health Institute demonstrates research advances in medical device interoperability to lower the cost of health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, announced today that it ... Report on Form 20-F that included audited financial statements ... version of Mindray,s Annual Report on Form 20-F is ...
... 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... the European League Against Rheumatism (EULAR) 2011 Annual Congress.  The ... London, United Kingdom, and will feature the abstracts as two ... scheduled oral presentation and the poster session will address the ...
Cached Medicine Technology:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2
(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
... recurrence after five-year mark, but numbers aren,t as high as ... News) -- The risk of relapse can linger for some ... doctors call systemic therapy, a new study found. , But, ... bright spot: the risk may not be as dire as ...
... Urged to End Role as It Did with ... For the second time in,recent weeks, international ... to withdraw its sponsorship and promotion of a ... company,s activities appear,to violate national law., Last ...
... SMBL ) announced today Stephen Hughes, Chairman and ... presentation at the Canaccord,Adams Global Growth Conference in Boston, ... Smart Balance,s presentation will be approximately 30 minutes ... questions, but,listeners will be able to hear the question-and-answer ...
... study fails to settle question about best treatment for ... The latest update from a European study that has ... decade leaves the debate about the advantages of aggressive ... survival seen for men who underwent surgery to remove ...
... Holland America Line has surpassed the,million-dollar mark in ... its On Deck for the Cure program, earning it ... will celebrate the milestone,this week with special receptions and ... corporate headquarters in Seattle., Since the program began ...
... Internet shopping today offers many benefits. You can research ... and purchase most anything by clicking a mouse. But ... the Internet, bypassing a traditional office visit or conversation ... Mayo Clinic Proceedings , researchers from Utah and several ...
Cached Medicine News:Health News:Risk of Breast Cancer Relapse Can Linger 2Health News:Risk of Breast Cancer Relapse Can Linger 3Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 2Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 3Health News:Smart Balance to Webcast Presentation at Canaccord Adams Global Growth Conference 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 2Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 4Health News:Researchers examine safety of Internet prescriber service providing erectile dysfunction medications 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
Medicine Products: